A critical literature review of health economic evaluations of rotavirus vaccination

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1272-1288

  Aballea, Samuel ^a   Millier, Aurelie ^a   Quilici, Sibilia ^b   Carroll, Stuart ^c   Petrou, Stavros ^d   Toumi, Mondher ^e  

^a CREATIV CEUTICAL   (France)

^b SANOFI PASTEUR   (France)

^c Sanofi Pasteur MSD   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

Cost effectiveness; Economic evaluations; Economic model; Pediatrics; Review; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ADAPTIVE IMMUNITY; BUDGET; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; DRUG EFFICACY; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INCIDENCE; MORTALITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; ROTAVIRUS GASTROENTERITIS; ROTAVIRUS INFECTION; SEASONAL VARIATION; SYSTEMATIC REVIEW; VACCINATION; VIRAL GASTROENTERITIS;

COST-EFFECTIVENESS; ECONOMIC EVALUATIONS; ECONOMIC MODEL; PEDIATRICS; REVIEW; ROTAVIRUS; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; GASTROENTERITIS; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; WORLD HEALTH;

EID: 84880660625     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24253     Document Type: Review

References (119)

1. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197-204; PMID:12764516.
2. Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R. Progress and barriers for the control of diarrhoeal disease. Lancet 2010; 376:63-7; PMID:20609988; http://dx.doi.org/10.1016/S0140-6736(10)60356-X.
3. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72; PMID:12737740; http://dx.doi.org/10.3201/eid0905.020562.
4. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6; PMID:16494759; http://dx.doi.org/10.3201/eid1202.050006.
5. Soriano-Gabarró M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25(Suppl):S7-11; PMID:16397431; http://dx.doi.org/10.1097/01.inf.0000197622. 98559.01.
6. Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27:281-97; PMID:19485425; http://dx.doi.org/10.2165/ 00019053-200927040-00002.
7. Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines 2011; 10:1037-51; PMID:21806398; http://dx.doi.org/10.1586/erv.11.65.
8. Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Pharmacoeconomics 2011; 29:439-54; PMID:21504245; http://dx.doi.org/10.2165/11207130-000000000-00000.
9. Plosker GL. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries. Drugs R D 2012; 12:239-44; PMID:23017130; http://dx.doi.org/10.2165/11208130-000000000-00000.
10. Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics 2011; 29:989-1009; PMID:21988293; http://dx.doi.org/10.2165/11207210-000000000-00000.
11. Plosker GL. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries. Paediatr Drugs 2012; 14:429-33; PMID:23013458.
12. Postma MJ, Jit M, Rozenbaum MH, Standaert B, Tu HA, Hutubessy RC. Comparative review of three costeffectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med 2011; 9:84; PMID:21740545; http://dx.doi.org/10.1186/1741- 7015-9-84.
13. Fruytier AC, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting. Value Health 2006; 9(Issue 6):A253; http://dx.doi.org/10.1016/S1098-3015(10)63361-X.
14. Dhont P, Trichard M, Largeron N, Rafia R, Bénard S. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. J Med Econ 2008; 11:431-48; PMID:19450097; http://dx.doi.org/10.3111/13696990802306162.
15. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 2009; 29:33-50; PMID:18948433; http://dx.doi.org/10.1177/0272989X08324955.
16. Nohynek H, Salo H, Renko M, Leino T. Finland introduces rotavirus vaccine into the national vaccination programme in September 2009. Euro Surveill 2009; 14:1-3; PMID:19728979.
17. Trichard M, Largeron N, Soum S, Saint-Sardos C. Budget impact of a universal rotavirus vaccination programme with Rotateq® in France. Value Health 2007; 10:A352; http://dx.doi.org/10.1016/S1098-3015(10)65253-9.
18. Huet F, Largeron N, Trichard M, Miadi-Fargier H, Jasso-Mosqueda G. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine 2007; 25:6348-58; PMID:17629598; http://dx.doi.org/10.1016/j.vaccine.2007.06.015.
19. Melliez H, Levybruhl D, Boelle PY, Dervaux B, Baron S, Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26:706-15; PMID:18166250; http://dx.doi.org/10.1016/j. vaccine.2007.11.064.
20. Standaert B, Parez N, Tehard B, Colin X, Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008; 6:199-216; PMID:19382820; http://dx.doi.org/10.1007/ BF03256134.
21. Benard S, Quilici S. Economic evaluation of a pentavalent universal rotavirus vaccination programme in France. European Society for Paediatric Infectious Diseases 27th Annual Meeting. Brussels (Belgium), June 9-13, 2009.
22. Hammerschmidt T, Forster J, Huppertz HI, Heininger U, Roos R, Standaert B. Epidemiological and economic impact of routine vaccination of infants against rotavirus gastroenteritis in Germany: a preliminary analysis. Value Health 2010; 13:A435-6.
23. Buesch K, Ezzat N, Trichard M, Largeron N. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal vaccination programme in Germany. Value Health 2007; 10(Issue 6):A437; http://dx.doi.org/10.1016/S1098- 3015(10)65514-3.
24. Greiner W. Potential health and economic outcomes of implementing universal rotavirus vaccination programme with Rotateq® in Europe-the example of Germany. European Society for Paediatric Infectious Diseases 26th Annual Meeting. Graz (Austria), May 13-17, 2008.
25. Brüggenjürgen B, Schmitter S, Ezzat N, Quilici S. Economic evaluation of universal pentavalent rotavirus vaccination programme in Germany. European Society for Paediatric Research 50th Annual Meeting. Hamburg (Germany), October 9-12, 2009.
26. Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, et al. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece. Acta Paediatr 2011; 100:732-9; PMID:21223372; http://dx.doi.org/10.1111/j.1651-2227.2010.02127.x.
27. Redmond S, Standaert B. Cost-effectiveness of universal rotavirus vaccination in Ireland: a preliminary analysis. Value Health 2009; 12:A423; http://dx.doi.org/10.1016/S1098-3015(10)75090-7.
28. Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011; 29:7463-73; PMID:21821085; http://dx.doi.org/10.1016/j.vaccine.2011.07.056.
29. Panatto D, Amicizia D, Ansaldi F, Marocco A, Marchetti F, Bamfi F, et al. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009; 27:3450-3; PMID:19200850; http://dx.doi.org/10.1016/j.vaccine.2009.01.054.
30. Giammanco MD, Coniglio MA, Pignato S, Giammanco G. An economic analysis of rotavirus vaccination in Italy. Vaccine 2009; 27:3904-11; PMID:19446934; http://dx.doi.org/10.1016/j.vaccine.2009.04.002.
31. Welte R, Jager J, van Duynhoven Y, de Wit M. Economic evaluation of rotavirus vaccination for the Netherlands. Value Health 2001; 4:131-131; http://dx.doi.org/10.1046/j.1524-4733.2001.40202-171.x.
32. Goossens LM, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26:1118-27; PMID:18215445; http://dx.doi.org/10.1016/j.vaccine. 2007.11.070.
33. Zomer TP, van Duynhoven YT, Mangen MJ, van der Maas NA, Vennema H, Boot H, et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008; 26:3757-64; PMID:18514975; http://dx.doi.org/10.1016/ j.vaccine. 2008.04.039.
34. Mangen MJ, van Duynhoven YT, Vennema H, van Pelt W, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010; 28:2624-35; PMID:20109593; http://dx.doi.org/10.1016/j.vaccine.2010.01.014.
35. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011; 11:462; PMID:21663620; http://dx.doi.org/10.1186/1471-2458-11-462.
36. André S, Silva C, Mateus MC, Standaert B. Costeffectiveness of vaccination with Rotarix in Portugal. Europaediatrics 3rd Annual Meeting. Istanbul (Turkey), June 14-17 2008.
37. Rubio-Terres C, Martin-Escudero V, Standaert B, Rodrigo C. Cost impact of paediatric rotavirus gastroenteritis (RVGE) and potential benefits of a universal vaccination programme in Spain. European Society for Paediatric Infectious Diseases 26th Annual Meeting. Graz (Austria), May 13-17, 2008.
38. Pérez-Rubio A, Luquero FJ, Eiros Bouza JM, Castrodeza Sanz JJ, Bachiller Luque MR, de Lejarazu RO, et al. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain. Infez Med 2011; 19:166-75; PMID:22037437.
39. Largeron N, Trichard M, Miadi-Fargier H, Trancart A, D'Ausilio A, Chicoye A. Cost-effectiveness analysis of rotavirus vaccination programme in the UK. Value Health 2006; 9(Issue 6):A243-4; http://dx.doi.org/10.1016/S1098-3015(10) 63332-3.
40. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential costeffectiveness of vaccination. Vaccine 2007; 25:3971-9; PMID:17400341; http://dx.doi.org/10.1016/j.vaccine. 2007.02.070.
41. Lorgelly PK, Joshi D, Iturriza Gómara M, Gray J, Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136:44-55; PMID:17335631; http://dx.doi.org/10.1017/S0950268807008151.
42. Martin A, Batty A, Roberts JA, Standaert B. Costeffectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009; 27:4520-8; PMID:19446594; http://dx.doi.org/10.1016/j.vaccine. 2009.05.006.
43. Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27:6121-8; PMID:19715781; http://dx.doi.org/10.1016/j.vaccine.2009.08.030.
44. Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, et al. An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe". Vaccine 2010; 28:7457-9; PMID:20846529; http://dx.doi.org/10.1016/j.vaccine. 2010.08.060.
45. de Soárez PC, Valentim J, Sartori AM, Novaes HM. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008; 23:221-30; PMID:18505602; http://dx.doi.org/10.1590/ S1020-49892008000400001.
46. Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008; 26:388-96; PMID:19069617.
47. Valentim-Estimates in the economic evaluations of vaccination programmes: the cases of rotavirus and varicella in Brazil. Value Health 2009; 12(Issue 7):A427; http://dx.doi.org/10.1016/S1098-3015(10)75110-X.
48. Constenla D, O'Ryan M, Navarrete MS, Antil L, Rheingans RD. [Potential cost effectiveness of a rotavirus vaccine in Chile]. Rev Med Chil 2006; 134:679-88; PMID:17130941; http://dx.doi.org/10.4067/S0034-98872006000600002.
49. De la Hoz F, Alvis N, Narváez J, Cediel N, Gamboa O, Velandia M. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010; 28:3856-64; PMID:20347057; http://dx.doi.org/10.1016/j. vaccine.2010.03.004.
50. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008; 8:103-16; PMID:18664280; http://dx.doi.org/10.1186/1471-2334-8-103.
51. Constenla D, Velázquez FR, Rheingans RD, Antil L, Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009; 25:481-90; PMID:19695142; http://dx.doi.org/10.1590/S1020- 49892009000600003.
52. Constenla D, Ortega-Barría E, Rheingans RD, Antil L, Sáez-Llorens X. [Economic impact of rotavirus vaccination in Panama] An Pediatr (Barc) 2008; 68:128-35; PMID:18341878; http://dx.doi.org/10.1157/ 13116227.
53. Clark AD, Walker DG, Mosqueira NR, Penny ME, Lanata CF, Fox-Rushby J, et al. Cost-effectiveness of rotavirus vaccination in peru. J Infect Dis 2009; 200(Suppl 1):S114-24; PMID:19817591; http://dx.doi.org/10.1086/605043.
54. Constenla D, Pérez-Schael I, Rheingans RD, Antil L, Salas H, Yarzábal JP. [Assessment of the economic impact of the antiretroviral vaccine in Venezuela]. Rev Panam Salud Publica 2006; 20:213-22; PMID:17316479; http://dx.doi.org/10.1590/S1020-49892006000900001.
55. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21:205-16; PMID:17612464; http://dx.doi.org/10.1590/S1020-49892007000300003.
56. Newall AT, Beutels P, Macartney K, Wood J, MacIntyre CR. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25:8851-60; PMID:18022735; http://dx.doi.org/10.1016/j.vaccine. 2007.10.009.
57. Wang XY, Riewpaiboon A, von Seidlein L, Chen XB, Kilgore PE, Ma JC, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009; 49:1202-10; PMID:19739973; http://dx.doi.org/10. 1086/605632.
58. Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93:52-8; PMID:17855438; http://dx.doi.org/10.1136/adc.2007. 117879.
59. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009; 339:b3653-65; PMID:19783581; http://dx.doi.org/10.1136/bmj.b3653.
60. Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 2011; 52:171-7; PMID:21288839; http://dx.doi.org/10.1093/cid/ciq094.
61. Chodick G, Waisbourd-Zinman O, Shalev V, Kokia E, Rabinovich M, Ashkenazi S. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Eur J Public Health 2009; 19:254-9; PMID:19221026; http://dx.doi.org/10.1093/eurpub/ckp005.
62. Igarashi A, Fukuda T, Orihara S, Suzuki H. TSutani K. Cost-utility analysis of rotavirus vaccine (Rotarix) in Japan. Value Health 2009; 12:A429; http://dx.doi.org/10.1016/S1098-3015(10)75119-6.
63. Kang HY, Kim KH, Kim JH, Kim HM, Kim JK, Kim MS, et al. Public Health and Economic Impact of Rotavirus Vaccination in Korea. Value Health 2010; 13:A549; http://dx.doi.org/10.1016/S1098-3015(11)73294-6.
64. Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. J Infect Dis 2009; 200(Suppl 1):S195-202; PMID:19817600; http://dx.doi.org/10.1086/605040.
65. Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health 2009; 12:888-98; PMID:19490550; http://dx.doi.org/10. 1111/j.1524-4733.2009.00534.x.
66. Wu CL, Yang YC, Huang LM, Chen KT. Costeffectiveness of childhood rotavirus vaccination in Taiwan. Vaccine 2009; 27:1492-9; PMID:19186200; http://dx.doi.org/10.1016/j.vaccine.2009.01.023.
67. Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health 2010; 41:114-25; PMID:20578490.
68. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25:373-80; PMID:16930784; http://dx.doi.org/10.1016/j.vaccine. 2006.07.029.
69. Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192:1720-6; PMID:16235169; http://dx.doi.org/10.1086/497339.
70. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009; 9:29; PMID:19159483; http://dx.doi.org/10.1186/1471-2458-9-29.
71. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192(Suppl 1):S133-45; PMID:16088797; http://dx.doi.org/10.1086/ 431513.
72. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119:684-97; PMID:17403839; http://dx.doi.org/10.1542/ peds.2006-2876.
73. Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27:4025-30; PMID:19389452; http://dx.doi.org/10.1016/j.vaccine.2009.04.030.
74. Weycker D, Sofrygin O, Kemner JE, Pelton SI, Oster G. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine 2009; 27:4930-7; PMID:19555715; http://dx.doi.org/10.1016/j. vaccine.2009.06.025.
75. Ortega O, El-Sayed N, Sanders JW, Abd-Rabou Z, Antil L, Bresee J, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009; 200(Suppl 1):S92-8; PMID:19817621; .
76. Tate JE, Rheingans RD, O'Reilly CE, Obonyo B, Burton DC, Tornheim JA, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J Infect Dis 2009; 200(Suppl 1):S76-84; PMID:19817618; http://dx.doi.org/10.1086/605058.
77. Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010; 202(Suppl):S108-15; PMID:20684689; http://dx.doi.org/10.1086/653578.
78. Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011; 29:3329-34; PMID:21241733; http://dx.doi.org/10.1016/j.vaccine. 2010.12.122.
79. Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200(Suppl 1):S16-27; PMID:19817595; http://dx.doi.org/10.1086/605026.
80. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: costeffectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200(Suppl 1):S28-38; PMID:19817610; http://dx.doi.org/10.1086/605033.
81. Toumi M, Vesikari T, Giaquinto C. Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix® versus RotaTeq®". Vaccine 2010; 28:7241; PMID:20831915; http://dx.doi.org/10.1016/j.vaccine.2010.08.086.
82. Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 2011; 7:734-48; PMID:21734466; http://dx.doi.org/10.4161/hv.7.7.15511.
83. Gray J, Vesikari T, Van Damme P, Giaquinto C, Mrukowicz J, Guarino A, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008; 46(Suppl 2):S24-31; PMID:18460969; http://dx.doi.org/10.1097/MPG.0b013e31816f78ee.
84. Pitzer VE, Viboud C, Lopman BA, Patel MM, Parashar UD, Grenfell BT. Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. J R Soc Interface 2011; 8:1584-93; PMID:21508015; http://dx.doi.org/10.1098/rsif.2011.0062.
85. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID:16394299; http://dx.doi.org/10.1056/ NEJMoa052664.
86. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al.; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/ NEJMoa052434.
87. Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43; PMID:15602194; http://dx.doi.org/10.1097/ 01.inf.0000141722.10130.50.
88. Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, et al. Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. PLoS One 2012; 7:e41720; PMID:22879893; http://dx.doi.org/10.1371/journal.pone. 0041720.
89. Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011; 365:337-46; PMID:21793745; .
90. Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin 2011; 7:563-8; PMID:21441783; http://dx.doi.org/10.4161/hv.7.5.15406.
91. Van Damme P, Giaquinto C, Huet F, Gothefors L, Maxwell M, Van der Wielen M; REVEAL Study Group. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007; 195(Suppl 1):S4-16; PMID:17387650; http://dx.doi.org/10.1086/516714.
92. Van Damme P, Giaquinto C, Maxwell M, Todd P, Van der Wielen M; REVEAL Study Group. Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study. J Infect Dis 2007; 195(Suppl 1):S17-25; PMID:17387648; http://dx.doi.org/10.1086/516715.
93. Bruijning-Verhagen P, Quach C, Bonten M. Nosocomial rotavirus infections: a meta-analysis. Pediatrics 2012; 129:e1011-9; PMID:22392170; http://dx.doi.org/10.1542/peds.2011-2779.
94. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006; 21:402-8; PMID:16877455; http://dx.doi.org/10.1093/heapol/ czl018.
95. Shepard DS. Cost-effectiveness in Health and Medicine. By Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). New York: Oxford University Press, 1996.
96. J Ment Health Policy Econ. 1999 Jun 1;2(2):91-92.
97. Brisson M, Sénécal M, Drolet M, Mansi JA. Healthrelated quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010; 29:73-5; PMID:19907361; http://dx.doi.org/10.1097/INF.0b013e3181b41506.
98. Huppertz HI, Forster J, Heininger U, Roos R, Neumann HU, Hammerschmidt T. The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila) 2008; 47:363-71; PMID:18270310; http://dx.doi.org/10.1177/0009922807310933.
99. Haagsma JA, Havelaar AH, Janssen BM, Bonsel GJ. Disability adjusted life years and minimal disease: application of a preference-based relevance criterion to rank enteric pathogens. Popul Health Metr 2008; 6:7; PMID:19114007; http://dx.doi.org/10.1186/1478-7954-6-7.
100. Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ 2008; 11:471-84; PMID:19450099; http://dx.doi.org/10.3111/13696990802321047.
101. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al.; New Vaccine Surveillance Network (NVSN). Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011; 53:245-53; PMID:21705316; http://dx.doi.org/10. 1093/cid/cir307.
102. Van Effelterre T, Soriano-Gabarró M, Debrus S, Claire Newbern E, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010; 138:884-97; PMID:20028612; http://dx.doi.org/10.1017/ S0950268809991245.
103. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012; 30:552-64; PMID:22133508; http://dx.doi.org/10.1016/j.vaccine.2011.11.064.
104. Atchison C, Lopman B, Edmunds WJ. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010; 28:3118-26; PMID:20197142; http://dx.doi.org/10.1016/j.vaccine.2010.02.060.
105. Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). [Erratum in: MMWR Recomm Rep. 2010 Aug 27;59] [33]. MMWR Recomm Rep 2009; 58(RR-2):1-25; PMID:19194371.
106. Ciarlet M, Schödel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 2009; 27(Suppl 6):G72-81; PMID:20006144; http://dx.doi.org/10. 1016/j.vaccine.2009.09.107.
107. Iturriza-Gómara M, Dallman T, Bányai K, Böttiger B, Buesa J, Diedrich S, et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2011; 139:895-909; PMID:20707941; http://dx.doi.org/10.1017/S0950268810001810.
108. Pitzer VE, Patel MM, Lopman BA, Viboud C, Parashar UD, Grenfell BT. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc Natl Acad Sci U S A 2011; 108:19353-8; PMID:22084114; http://dx.doi.org/10.1073/pnas.1110507108.
109. Clark HF, Lawley D, DiStefano D, Matthijnssens J, Dinubile MJ. Distribution of rotavirus genotypes causing nosocomial and community-acquired acute gastroenteritis at the Children's Hospital of Philadelphia in the new rotavirus vaccine era. Hum Vaccin 2011; 7:1118-23; PMID:22048265; http://dx.doi.org/10.4161/hv.7.11.17820.
110. Vesikari T, Ujari M, Renko M, Hemming M, Risku M, Salminen M, et al. Results from 2 years of surveillance of hospitalised children with acute gastroenteritis following introduction of routine rotavirus vaccination in Finland. 30th Annual Meeting of the European Society For Paediatric Infectious Diseases.Thessaloniki, Greece, May 8-12, 2012, 2012, p. 1-2.
111. Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29:2791-6; PMID:21320539; http://dx.doi.org/10.1016/j.vaccine.2011.01.104.
112. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011; 30(Suppl):S21-4; PMID:21183836; http://dx.doi.org/10.1097/INF.0b013e3181fefc51.
113. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID:16394299; http://dx.doi.org/10.1056/ NEJMoa052664.
114. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010; 29:957-63; PMID:20442684; http://dx.doi.org/10.1097/INF.0b013e3181e28e6e.
115. Castilla J, Beristain X, Martínez-Artola V, Navascués A, García Cenoz M, Alvarez N, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine 2012; 30:539-43; PMID:22122860; http://dx.doi.org/10. 1016/j.vaccine.2011.11.071.
116. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51; PMID:19491186; http://dx.doi.org/10.1001/jama.2009.756.
117. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2:169-80; PMID:8401453; http://dx.doi.org/10.1007/BF00435221.
118. Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in health and medicine. New York: Oxford University Press (1996).
119. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2:169-80; PMID:8401453; http://dx.doi.org/10.1007/BF00435221.